Jefferies Financial Group Inc. Takes $1.79 Million Position in Neurocrine Biosciences, Inc. $NBIX

Jefferies Financial Group Inc. acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 2nd quarter, Holdings Channel.com reports. The fund acquired 10,630 shares of the company’s stock, valued at approximately $1,792,000.

A number of other large investors have also bought and sold shares of NBIX. Geneos Wealth Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. DJE Kapital AG bought a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $28,000. Basecamp Wealth Advisors LLC raised its holdings in shares of Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after acquiring an additional 204 shares during the period. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth $33,000. Finally, Meeder Asset Management Inc. lifted its position in Neurocrine Biosciences by 651.6% in the 4th quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock valued at $33,000 after acquiring an additional 202 shares in the last quarter. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Trading Down 1.2%

Neurocrine Biosciences stock opened at $154.06 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $122.14 and a 12 month high of $186.12. The stock’s 50 day moving average is $166.77 and its 200-day moving average is $149.43. The company has a market capitalization of $15.66 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 0.72 and a beta of 0.39.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping analysts’ consensus estimates of $1.65 by $1.20. The company had revenue of $959.00 million for the quarter, compared to analyst estimates of $891.16 million. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%.The firm’s quarterly revenue was up 39.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.65 earnings per share. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 7.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Morgan Stanley lowered their target price on Neurocrine Biosciences from $196.00 to $182.00 and set an “equal weight” rating for the company in a report on Thursday, August 13th. Guggenheim boosted their target price on Neurocrine Biosciences from $200.00 to $222.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings upgraded Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a research note on Tuesday. Wall Street Zen downgraded Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Sunday, August 9th. Finally, JPMorgan Chase & Co. raised their target price on shares of Neurocrine Biosciences from $177.00 to $185.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $200.86.

Insider Activity

In other news, Director Stephen A. Sherwin sold 25,000 shares of Neurocrine Biosciences stock in a transaction on Friday, June 5th. The stock was sold at an average price of $165.32, for a total transaction of $4,133,000.00. Following the completion of the sale, the director owned 15,860 shares of the company’s stock, valued at approximately $2,621,975.20. This trade represents a 61.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ingrid Delaet sold 8,433 shares of the business’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $178.72, for a total transaction of $1,507,145.76. Following the completion of the sale, the insider directly owned 16,225 shares of the company’s stock, valued at approximately $2,899,732. The trade was a 34.20% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 114,375 shares of company stock worth $18,994,756. Corporate insiders own 4.60% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.